First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

April 28, 2025

Study Completion Date

April 28, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

SAT-3247

SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.

DRUG

matched placebo

matched placebo

Trial Locations (2)

3153

Veritus, Bayswater

5000

CMAX, Adelaide

All Listed Sponsors
lead

Satellos Bioscience, Inc.

INDUSTRY

NCT06565208 - First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort | Biotech Hunter | Biotech Hunter